Bespoke Neuroblastoma Therapy Weaponizes Cell Metabolism

Summary: Two existing medications show promise in the treatment of the deadly childhood cancer, neuroblastoma. Phenformin and AZD3965 exploit the metabolic hunger of the disease to kill cancer cells without inflicting excessive damage to healthy tissue.

Source: Virginia Commonwealth University

Preclinical research from VCU Massey Cancer Center published recently in the Proceedings of the National Academy of Sciences shows that the combination of two existing drugs can exploit the metabolic “hunger” of a particularly aggressive type of neuroblastoma to kill cancer cells without inflicting too much collateral damage to healthy tissue.

Neuroblastoma – a type of cancer that strikes the nervous system of very young children – is one of the deadliest pediatric cancers. And children whose neuroblastoma overexpresses the gene MYCN tend to have the worst prognosis.

While medical advancements have led to high cure rates among pediatric blood cancers, neuroblastoma has proven much more challenging to treat, largely because the gene that makes this cancer so deadly is a tough one to target.

“MYCN is a transcription factor, and it’s very difficult to drug transcription factors,” said study senior author Anthony Faber, Ph.D., co-leader of the Developmental Therapeutics research program and Natalie N. and John R. Congdon, Sr. Endowed Chair of Cancer Research at VCU Massey Cancer Center and associate professor in the Philips Institute for Oral Health Research at the VCU School of Dentistry.

“So, the next best thing is to target what MYCN does in the cell. One thing it does is to crank up metabolic activity – what it’s doing to keep the cell alive – and we can work that against itself.”

These neuroblastoma cells exist on the brink of metabolic overdrive, gobbling up energy stores as quickly as the cell can replenish them, so Faber’s team sought ways to push these cells over the edge, without harming normal cells in the process.

The researchers screened 20 metabolic drug combinations in cancer cells originating from nearly 1,000 different patients and found that neuroblastoma with high MYCN expression was particularly sensitive to a cocktail containing two drugs: phenformin and AZD3965.

Phenformin, which blocks complex I on the surface of mitochondria – the sub-cellular compartment where energy production occurs – was developed in 1957 to treat diabetes. Although the Food and Drug Administration took phenformin off the market in the 1970s following a string of deaths, it’s still in use elsewhere in the world and is starting to make a comeback in the U.S. as a cancer drug. Right now, phenformin is being tested in a phase I clinical trial for melanoma.

This shows the outline of a girl and a brain
Neuroblastoma – a type of cancer that strikes the nervous system of very young children – is one of the deadliest pediatric cancers. Image is in the public domain

AZD3965, a much newer type of drug that blocks MCT1 rectors on the surface of cells, is also under phase I clinical investigation, in this case as a treatment for many different types of cancer. MCT1 receptors ferry lactate – another source of energy – out of the cell. But when MCT1 is blocked and lactate accumulates, the cell stops using it to make energy.

Since the receptors targeted by phenformin and AZD3965 participate in energy production through two distinct pathways, blocking them both at once should dramatically disrupt the cellular power supply, leading to stress and ultimately cell death.

Faber’s team tested this idea by using mice seeded with MYCN-amplified neuroblastoma patient cells and found that animals treated with both drugs saw greater tumor shrinkage than animals given either drug alone, and the cocktail was well tolerated.

“The data we got with AZD3965 in combination with phenformin might get people to reconsider phenformin,” said study lead author Krista Dalton, M.Eng., a Ph.D. student in the VCU Philips Institute for Oral Health Research. “In combination, where we can use lower doses, phenformin might have better tolerability than it previously did on its own.”

Funding: Funding for this project was provided by the National Cancer Institute (R01CA215610-01) and Massey’s NCI Cancer Center Support Grant (P30 CA016059).

Additional authors on the study include VCU researchers Timothy Lochmann, Ph.D., Konstantinos Floros, Ph.D., Marissa Calbert, Richard Kurupi, M.S., Sosipatros Boikos, M.D., member of Massey’s Developmental Therapeutics research program, Mikhail Dozmorov, Ph.D., member of Massey’s Cancer Biology research program, Sivapriya Ramamoorthy, Ph.D., Madhavi Puchalapalli, M.S., Bin Hu, Lisa Shock, Ph.D., Cancer Biology member at Massey, Jennifer Koblinski, Ph.D., director of the Cancer Mouse Models Core and Cancer Biology member at Massey; Giovanna Stein, Joseph McClanaghan, Ellen Murchie, Regina Egan, Patricia Greninger, and Cyril Benes, Ph.D., of Harvard Medical School; and John Glod, M.D., Ph.D., of the National Cancer Institute.

About this brain cancer research news

Source: Virginia Commonwealth University
Contact: Erin Hare – Virginia Commonwealth University
Image: The image is in the public domain

Original Research: Closed access.
Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma” by Anthony Faber et al. PNAS


Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma

MYCN-amplified neuroblastoma is a lethal subset of pediatric cancer. MYCN drives numerous effects in the cell, including metabolic changes that are critical for oncogenesis.

The understanding that both compensatory pathways and intrinsic redundancy in cell systems exists implies that the use of combination therapies for effective and durable responses is necessary. Additionally, the most effective targeted therapies exploit an “Achilles’ heel” and are tailored to the genetics of the cancer under study.

We performed an unbiased screen on select metabolic targeted therapy combinations and correlated sensitivity with over 20 subsets of cancer.

We found that MYCN-amplified neuroblastoma is hypersensitive to the combination of an inhibitor of the lactate transporter MCT1, AZD3965, and complex I of the mitochondrion, phenformin. Our data demonstrate that MCT4 is highly correlated with resistance to the combination in the screen and lowly expressed in MYCN-amplified neuroblastoma. Low MCT4 combines with high expression of the MCT2 and MCT1 chaperone CD147 in MYCN-amplified neuroblastoma, altogether conferring sensitivity to the AZD3965 and phenformin combination.

The result is simultaneous disruption of glycolysis and oxidative phosphorylation, resulting in dramatic disruption of adenosine triphosphate (ATP) production, endoplasmic reticulum stress, and cell death. In mouse models of MYCN-amplified neuroblastoma, the combination was tolerable at concentrations where it shrank tumors and did not increase white-blood-cell toxicity compared to single drugs.

Therefore, we demonstrate that a metabolic combination screen can identify vulnerabilities in subsets of cancer and put forth a metabolic combination therapy tailored for MYCN-amplified neuroblastoma that demonstrates efficacy and tolerability in vivo.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.